ADHD Drug CTx-1301 Receives Complete Response Letter - Summary - MDSpire

ADHD Drug CTx-1301 Receives Complete Response Letter

  • By

  • Kathryn Wighton

  • June 2, 2026

Share

Objective:

To report on the FDA's Complete Response Letter regarding CTx-1301 for ADHD.

Key Findings:
  • The FDA's feedback was limited to specific CMC information requests.
  • CTx-1301 is designed as a once-daily, multi-core tablet for ADHD.
  • The product is under evaluation via the FDA’s 505(b)(2) pathway.
Interpretation:

N/A

Limitations:
  • The FDA letter was not released to the public.
  • CTx-1301 remains investigational and is not approved for ADHD.
Conclusion:

N/A

Original Source(s)

ADHD Drug CTx-1301 Receives Complete Response Letter

  • by Kathryn Wighton

  • June 2, 2026

Related Content

Institutional trauma, absence of accountability, and psychopathology in a juvenile serial homicide case

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Predictive value of antioxidant and thyroid function indicators for non-suicidal self-injury in adolescents with major depressive disorder